Arrowhead Pharmaceuticals secured FDA approval for its RNA interference therapy Redemplo (plozasiran) for familial chylomicronemia syndrome, marking the company’s transition into a commercial-stage RNAi developer. The approval establishes a lower-priced competitive entry versus incumbents and sets the stage for Arrowhead to commercialize its platform beyond clinical proof of concept. The newly approved product highlights RNAi’s progress from experimental modality to approved therapeutics. The market entry will likely spark pricing and access debates with rivals, given the rarity of the indication and competing antisense-based therapies. For investors and biotech strategists, the approval validates in vivo RNAi delivery chemistry and execution; Arrowhead can now leverage commercial revenues while advancing next-wave programs across metabolic and rare disease targets.